BioCheck, Inc. - An Immunoassay Company

About Us
MORE ABOUT BIOCHECK INC.
History Biography

HISTORY

BioCheck, located in the San Francisco Bay Area, was founded in January 1997, to develop and manufacture high-quality enzyme immunoassay test kits for the worldwide biomedical, pharmaceutical, and scientific research markets. The founders have brought over four decades of experience, enabling BioCheck to quickly provide reliable and sensitive products to its customers.
Every BioCheck EIA kit is manufactured according to U.S. Food and Drug Administration (FDA) Good Manufacturing Practice standards in our 15,000 square foot facility in Foster City, California. At the present time, the company manufactures over 40 EIA test kits, of which 17 have been FDA cleared. The company also has U.S. FDA Certificates to Foreign Governments and Certificates of Exportability for many of its products.
BioCheck's EIA kits have also been registered in Brazil, India, Italy, Taiwan, Turkey, and the United Kingdom. We also work with distributors to deliver our products to countries in Central and South America, Europe, the Middle East, and Asia.
BioCheck is currently working with leading-edge biopharmaceutical companies to take advantage of advances in genomics in order to develop novel test kits that improve earlier and accurate detection of diseases.

Top of Page

EXECUTIVE BIOGRAPHY

John Chen, Ph.D
Chief Executive Officer & President
John Chen, Ph.D., co-founded BioCheck in January 1997 and is currently the President and CEO of BioCheck. In 2003, Dr. Chen founded EverNew Biotech, Inc. EverNew Biotech is focusing on developing, manufacturing and marketing Point-of-Care diagnostic kits. He currently serves as the President and CEO of EverNew Biotech. In 1998 he was a cofounder of Rapid Diagnostics, Inc., a company that specialized in rapid test diagnostics for the detection of Drugs of Abuse. He served as a Director at Rapid Diagnostics until the company was acquired by ICN Pharmaceuticals in 2002. Prior to co-founding BioCheck, Dr. Chen co-founded Medix Biotech in 1983. Medix Biotech specialized in monoclonal/polyclonal antibodies, enzyme immunoassay test kits, and rapid test kits. Dr. Chen served as CEO of the company until Medix Biotech was fully acquired by Genzyme Corporation in 1992. Dr. Chen remained as VP of Research and Development of Medix until 1995. From 1981 to 1983, Dr. Chen co-founded Pacific Biotech where he was instrumental in the development of the first rapid pregnancy test. Pacific Biotech was acquired by Eli Lilly in 1990. He previously served research scientist roles at Sigma Chemical, Mallinckrodt, and Beckman Instruments. Dr. Chen holds a B.S. in Chemistry from Tunghai University in Taiwan and a Ph.D. in Biochemistry from the University of Alberta, Edmonton.
Dr. Chen is a biochemist/clinical chemist with over 30 years of research and development experience. He has strong industry contacts and is renowned for his superior assay development capabilities. Over the years, he has developed more than 50 EIA and rapid tests in different formats, many of which have been approved for marketing by the FDA. His technical expertise in immunology and biochemistry is enhanced by his proven ability to facilitate technology transfer from research and development to manufacturing. His reputation of successfully managing the technical aspects of diagnostics has been instrumental in the creation of partnerships with other biotechnology and pharmaceutical companies.

Top of Page

BioCheck, Inc., 323 Vintage Park Dr., Foster City, CA 94404 U.S.A.
Phone: (650) 573-1968 | Fax: (650) 573-1969 | eMail: info@biocheckinc.com
© 2002 Biocheck, Inc.

	HISTORY
	BioCheck, located in the San Francisco Bay Area, was founded in January 1997, to develop and manufacture high-quality enzyme immunoassay test kits for the worldwide biomedical, pharmaceutical, and scientific research markets. The founders have brought over four decades of experience, enabling BioCheck to quickly provide reliable and sensitive products to its customers. Every BioCheck EIA kit is manufactured according to U.S. Food and Drug Administration (FDA) Good Manufacturing Practice standards in our 15,000 square foot facility in Foster City, California. At the present time, the company manufactures over 40 EIA test kits, of which 17 have been FDA cleared. The company also has U.S. FDA Certificates to Foreign Governments and Certificates of Exportability for many of its products. BioCheck's EIA kits have also been registered in Brazil, India, Italy, Taiwan, Turkey, and the United Kingdom. We also work with distributors to deliver our products to countries in Central and South America, Europe, the Middle East, and Asia. BioCheck is currently working with leading-edge biopharmaceutical companies to take advantage of advances in genomics in order to develop novel test kits that improve earlier and accurate detection of diseases.
Top of Page
	EXECUTIVE BIOGRAPHY
	John Chen, Ph.D Chief Executive Officer & President John Chen, Ph.D., co-founded BioCheck in January 1997 and is currently the President and CEO of BioCheck. In 2003, Dr. Chen founded EverNew Biotech, Inc. EverNew Biotech is focusing on developing, manufacturing and marketing Point-of-Care diagnostic kits. He currently serves as the President and CEO of EverNew Biotech. In 1998 he was a cofounder of Rapid Diagnostics, Inc., a company that specialized in rapid test diagnostics for the detection of Drugs of Abuse. He served as a Director at Rapid Diagnostics until the company was acquired by ICN Pharmaceuticals in 2002. Prior to co-founding BioCheck, Dr. Chen co-founded Medix Biotech in 1983. Medix Biotech specialized in monoclonal/polyclonal antibodies, enzyme immunoassay test kits, and rapid test kits. Dr. Chen served as CEO of the company until Medix Biotech was fully acquired by Genzyme Corporation in 1992. Dr. Chen remained as VP of Research and Development of Medix until 1995. From 1981 to 1983, Dr. Chen co-founded Pacific Biotech where he was instrumental in the development of the first rapid pregnancy test. Pacific Biotech was acquired by Eli Lilly in 1990. He previously served research scientist roles at Sigma Chemical, Mallinckrodt, and Beckman Instruments. Dr. Chen holds a B.S. in Chemistry from Tunghai University in Taiwan and a Ph.D. in Biochemistry from the University of Alberta, Edmonton. Dr. Chen is a biochemist/clinical chemist with over 30 years of research and development experience. He has strong industry contacts and is renowned for his superior assay development capabilities. Over the years, he has developed more than 50 EIA and rapid tests in different formats, many of which have been approved for marketing by the FDA. His technical expertise in immunology and biochemistry is enhanced by his proven ability to facilitate technology transfer from research and development to manufacturing. His reputation of successfully managing the technical aspects of diagnostics has been instrumental in the creation of partnerships with other biotechnology and pharmaceutical companies.
Top of Page